Reddy's have no intent on pushing Fonda any further huh? Do you actually know what you're talking about, or are you just guessing?
If what you say is fact, then why was it reported in February that Reddy's are going to be expanding the capacity of their API plant ?
"The manufacturing capacities of some of the fast moving drugs such as Omeprazole, Atorvastatin, Ciprofloxacin HCL, Fondaparinux Sodium, Metoprolol Succinate, Clopidogrel Bisulphate and Fexofenadine Hydrochloride are set to go up considerably once the expansion takes place"
Why would Reddy's not be pushing Fonda any further when they only have a limited share of the hospital market-When it's been suggested that the Aspen‐Mylan deal is likely to of phased out AG sales . There's also the imminent EU approval that they'll need to scale up to, especially in light of the recently published study data which is extremely positive for Fonda over LWMHs ( ACS), which should be particularly favorable in the EU and encourage off label use in US- it also promotes the possibility for a large scale clinical trial in the US. No analysts have reported that the market is set to contract anytime soon, infact the opposite has been suggested. The market risk isn't oral drugs, it's the possibility of new entries into the Fonda market.
If your mail is that offices will be cleared out by June 30, Should holders also expect a Fonda offer by June 30?
ACL Price at posting:
5.7¢ Sentiment: Hold Disclosure: Not Held
